Physician profile
Yu Zhao
NPI 1912923707
$1,314.70
in general payments reported to CMS, 2019-2025
16 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $109 · 2021: $11.91 · 2022: $36.42 · 2023: $275 · 2024: $479 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.65 | 2023-2025 | Ubrelvy, Qulipta |
| Abbott Laboratories | $215.35 | 2023-2025 | Infinity |
| Biogen, INC. | $168.37 | 2019-2023 | Tysabri, Vumerity |
| Neurocrine Biosciences, INC. | $142.40 | 2023-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $89.14 | 2021-2025 | Nuplazid |
| Akcea Therapeutics, INC. | $81.96 | 2019 | |
| Amgen INC. | $74.61 | 2024 | Uplizna |
| Horizon Therapeutics Plc | $74.04 | 2020-2023 | Uplizna |
| Sumitomo Pharma America, INC. | $51.82 | 2023-2024 | Aptiom |
| Adamas Pharmaceuticals, INC. | $30.44 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.98 | 2019 | |
| Ge Healthcare | $16.13 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.83 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.82 | 2023 | Austedo |
| Lilly USA, LLC | $13.71 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.